N‐Coumaroyldopamine and N‐caffeoyldopamine increase cAMP via beta 2‐adrenoceptors in myelocytic U937 cells
Author:
- 1 April 2005
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 19 (6) , 497-502
Abstract
N‐Caffeoyldopamine is a phytochemical found in various plants, including cocoa (Theobroma cacao L.). N‐caffeoyldopamine and its natural analogs (N‐cinnamoyldopamine, N‐coumaroyldopamine, N‐feruloyldopamine, and N‐sinapoyldopamine) were synthesized and investigated to determine their potency as β‐adrenoceptor agonists, because they have chemical structural moieties found in β‐adrenoceptor agonists. Among the compounds tested in this study, N‐coumaroyldopamine and N‐caffeoyldopamine were the two most potent compounds, able to increase cAMP at the concentrations < 0.05 µM in U937 cells. The decreasing order of potency was N‐coumaroyldopamine < N‐caffeoyldopamine < N‐feruloyldopamine < N‐sinapoyldopamine < N‐cinnamoyldopamine. Using β2‐specific antagonists (butoxamine and ICI 118551), N‐coumaroyldopamine and N‐caffeoyldopamine were found to increase cAMP via β2‐adrenoceptors in U937 cells. In producing cAMP in U937 cells, N‐coumaroyldopamine and N‐caffeoyldopamine were as potent as several well‐known β2‐adrenoceptor agonists (salbutamol, procaterol, and fenoterol). These results indicate that N‐coumaroyldopamine and N‐caffeoyldopamine are potent compounds able to increase cAMP via β2‐adrenoceptors in U937 cells, and may have potential effects on human health.—Park, J. B. N‐Coumaroyldopamine and N‐caffeoyldopamine increase cAMP via beta 2‐adrenoceptors in myelocytic U937 cells. FASEB J . 19, 497–502 (2005)Keywords
This publication has 41 references indexed in Scilit:
- β-Adrenoceptor polymorphisms and heart failureTrends in Molecular Medicine, 2004
- Cardiovascular Safety of ??2-Adrenoceptor Agonist Use in Patients with Obstructive Airway DiseaseDrugs & Aging, 2004
- Vasodilating β-adrenoceptor blockers as cardiovascular therapeuticsPharmacology & Therapeutics, 2003
- The β-Adrenergic ReceptorsHerz, 2002
- α1-Adrenoceptor Antagonists. 4. Pharmacophore-Based Design, Synthesis, and Biological Evaluation of New Imidazo-, Benzimidazo-, and Indoloarylpiperazine DerivativesJournal of Medicinal Chemistry, 2002
- β-Adrenoceptor agonists and asthma—100 years of developmentEuropean Journal of Pharmacology, 2002
- Long-Acting β2-AgonistsAmerican Journal of Respiratory Medicine, 2002
- Recent Progress in .ALPHA.1-Adrenoceptor Pharmacology.Biological and Pharmaceutical Bulletin, 2002
- Identification and functional characterization of α2-adrenoceptor polymorphismsTrends in Pharmacological Sciences, 2001
- Alpha-adrenoceptor subtypesPharmacological Research, 2001